The aim of the present study was to integrate all the eligible studies and investigate whether the transforming growth factor-b1 (TGF-b1) gene polymorphisms are correlated with postmenopausal osteoporosis (PMOP) risk.
INTRODUCTION

P
ostmenopausal osteoporosis (PMOP) is the most common bone disease, and features bone loss and susceptibility to fragility fractures that are associated with a low bone mineral density (BMD). 1 PMOP is among the most prevalent metabolic bone diseases in postmenopausal women. 2, 3 Although PMOP has been described decades ago, its exact mechanisms remain poorly understood. 4 Genetic or acquired disorders can compromise gains in bone quantity and quality leading to osteoporosis early in life. 5 Previous studies indicated that low BMD was a major risk factor for PMOP and was highly heritable. 6, 7 Besides, many association studies have shown that genes and genetic factors might be involved in the pathogenesis of PMOP. [8] [9] [10] Recently, many studies deduced that transforming growth factor superfamily catalyzed enzymes for osteoporosis. Transforming growth factor-b1 (TGF-b1), a member of the transforming growth factor superfamily, is abundant in bone and has been implicated as an important regulator of both bone formation and resorption, 11 which can stimulate proliferation or differentiation of preosteoblasts as well as inhibit mature osteoclasts and proliferation of mononuclear osteoclast precursors in vitro. 12 Molecular biological evidence showed that polymorphisms in the TGF-b result in a Leu ! Pro substitution at amino acid 10, which includes a T ! C transition at nucleotide 29 and a T ! C transition at nucleotide 869 in the region encoding the signal sequence. 13, 14 This change influenced the bone remodeling, indicating that genetic polymorphisms of the T29C and T869C genes might be associated with increased risk for osteoporosis. Recently, significant association has been found between TGF-b1 T869C and TGF-b1 T29C polymorphisms and PMOP in several studies. But the results of these studies are complex and even opposite. 13,15 -21 Furthermore, no consolidated reports have been conducted to investigate the associations between TGF-b1 T869C and TGF-b1 T29C polymorphisms and PMOP. Therefore, we performed this meta-analysis to make contribution to obtain a more exact evaluation of the associations between TGF-b1 T869C and TGF-b1 T29C polymorphisms and PMOP risk.
MATERIALS AND METHODS
Literature Search
Databases including PubMed, EMBASE, Web of Science, and the Cochrane Library were searched for the eligible casecontrol studies that examined the relationship between TGF-b1 polymorphisms (TGF-b1 T869C and TGF-b1 T29C) and the susceptibility to PMOP. The following search terms were used: (Postmenopausal osteoporosis OR PMOP) AND (Transforming growth factor-b1 OR TGF-b1 OR TGF-b1 T869C OR TGF-b1 T29C) AND (polymorphism OR single nucleotide polymorphism OR SNP OR variation). There were no language restrictions in our study selection. Secondary searches of unpublished literature were conducted by searching the reference lists of the selected studies and reviews.
Inclusion and Exclusion Criteria
The inclusion criteria of our meta-analysis were as follows: case-control study; evaluation of PMOP risk and at least one of these identified TGF-b1 gene polymorphisms (TGF-b1 T869C and TGF-b1 T29C); and sufficient data, including number or frequency of alleles and genotypes. The exclusion criteria were reviews or case reports that were not case-control studies, no available data reported, and duplicated reports.
Data Extraction
Data from the eligible studies were extracted according to the inclusion and exclusion criteria by 2 authors, and a consensus was reached. For each study, the following data were collected: author list, year of publication, ethnicity, sample size, alleles, and genotypes of TGF-b1 T869C and TGF-b1 T29C polymorphisms. Furthermore, we also evaluated whether the genotype distributions of the control group followed the HardyWeinberg equilibrium (HWE).
Data Synthesis and Statistical Analysis
Odds ratio (OR) and 95% confidence interval (CI) were calculated to evaluate the association between TGF-b1 T869C and TGF-b1 T29C polymorphisms and PMOP risk. Allele contrast (C vs T), heterozygote (CT vs TT), homozygote (CC vs TT), dominant (CT/CC vs TT), and recessive (CC vs CT/TT) models were used to evaluate the relationship between TGF-b1 T869C and TGF-b1 T29C polymorphisms and PMOP risk. The assumption that there was heterogeneity was verified by a x 2 -based Q statistical test and quantified by I 2 metric value. If I 2 value is >50% or P < 0.10, suggesting that an obvious heterogeneity existed, ORs were pooled by random effect model; otherwise, the fixed effect model was used. Sensitivity analysis was performed to assess the impact of each study on the combined effect of the present meta-analysis and subgroup analysis was performed according to the ethnicity of the study populations. All metaanalyses were performed using Stata 12.0 software (StataCorp, College Station, TX) and a P value below 0.05 was considered statistically significant. This is a systematic review about literatures, so ethical approval was not necessary for our research.
RESULTS
Study Characteristics
A total of 8 studies 13, [15] [16] [17] [18] [19] [20] [21] involving 1851 cases and 2247 controls eventually satisfied the eligibility criteria ( Figure 1 ). Three studies 15, 17, 18 reported both alleles and genotypes of Figures 2 and 3) .
With regard to TGF-b1 T29C polymorphism, significant association was also observed (TGF-b1 T29C-CT vs TT: OR ¼ 1.25, 95% CI ¼ 1.02-1.53, P ¼ 0.032; CT/CC vs TT: OR ¼ 1.37, 95% CI ¼ 1.02-1.84, P ¼ 0.035), as shown in Table 2 no significant association in Caucasian population (Table 2 and Figure 4 ).
Sensitivity Analysis and Publication Bias
We eliminated the studies 13, 15, 16 that were not consistent with the HWE to estimate the sensitivity of our study and we found that the results of association between TGF-b1 T869C and TGF-b1 T29C polymorphisms and PMOP were relatively stable and credible. Furthermore, we did not assess publication bias because the number of studies analyzed was less than 10.
DISCUSSION
PMOP, an important health problem among postmenopausal women, is such a common skeletal disease characterized by skeletal fragility resulting in fractures from relatively minor trauma that several risk factors [22] [23] [24] [25] [26] may play an important role in the etiology and progression. Recently, PMOP is considered as an immune disease due to the fact that several cytokines and immune factors 8, 10 have been observed in the etiology of PMOP, such as TGF-b, 17 ,18 IL-6, 27 , IL-10, 17 , IL-17, 26 , etc. Among these genetic factors, TGF-b1 that plays an important role in the regulation of both bone formation and resorption, tissue recycling, and immune response has been widely studied in both Asian and Caucasian patients. 13, [15] [16] [17] [18] [19] [20] [21] Utennam et al 20 evaluated the association of T869C, C-509T, and G915C of the TGF-b1 gene with BMD serum TGF-b1 levels in 278 postmenopausal female osteoporosis subjects and 95 postmenopausal female control subjects and they concluded that T869C polymorphism of the TGF-b1 gene had an impact on decreased serum TGF-b1 levels and influenced susceptibility to osteopenia/osteoporosis in Thai women, which was consistent with the results of studies by Yamada et al 13, 15 and Lau et al. 19 Tural et al 17 investigated the association between osteoporosis and TGF-b1 polymorphism in 146 osteoporotic and 97 healthy control women. However, they did not found any difference between the groups regarding TGF-b1 genotype distribution and allele frequencies. Due to these conflicting results, it is necessary to conduct a comprehensive study to determine whether the polymorphisms of TGF-b1 gene (TGF-b1 T869C and TGF-b1 T29C polymorphisms) are associated with the susceptibility to PMOP.
In our meta-analysis, significant association was observed between TGF-b1 T869C polymorphism and PMOP risk, which was consistent with 2 studies 15, 20 ; however, another 2 studies 17, 18 reported opposite results. In our opinion, 2 factors may be contributed to these controversial results. First, the genotype distribution in the control subjects in the study by Yamada et al 15 was not consistent with HWE, which might have an effect on the overall results. Second, different sampling methods and environmental factors might also result in the overall results and the difference between overall results and individual results. Furthermore, in the subgroup analysis of ethnicity, there was significant association between TGF-b1 T869C polymorphism and PMOP risk in Asian populations, while no association was observed in Caucasian patients. We believe that 2 things may have contributed to this difference: first, genetic factors may vary from different ethnicities, suggesting that ancestral genetic factors may increase the risk of developing PMOP. Second, only 1 study 17 reported the association in Caucasian population, suggesting that no sufficient sample size and statistical power could be based on which to assess the relationship between TGF-b1 T869C polymorphism and PMOP risk in Caucasians. Besides, different methods of genotype analysis and the source of control individuals may be important contributors to these contradictory results.
With regard to TGF-b1 T29C polymorphism, significant association was also observed in our study and when stratified by ethnicity, significant association was also observed in Asian population, while there was no significant association in Caucasian population. However, Langdahl et al 21 studied the TGF-b1 T29C polymorphism using restriction fragment length polymorphism and sequencing in 296 osteoporotic patients with vertebral fractures and 330 normal individuals and the results suggested that TGF-b1 T29C polymorphism was not differently distributed among osteoporotic patients and normal controls. Therefore, they made the conclusion that TGF-b1 T29C polymorphism might not be a risk in the etiology of PMOP, which was inconsistent with our results. Sampling methods and the publication bias might be contributors to this significant difference. Langdahl et al 21 conducted their studies in Caucasian populations, in which no association was observed, while other studies 13, 16, 19 were performed in Asian populations and their results suggested that TGF-b1 T29C polymorphism was significantly associated with PMOP. Different ethnicity, sample size, and sampling methods might play an important role in this difference.
Despite a comprehensive analysis of the association between TGF-b1 gene polymorphisms (TGF-b1 T869C and TGF-b1 T29C), and the risk of developing PMOP, there are some limitations that should be addressed. First, the number of studies that were included in this analysis described a total of 1851 cases and 2247 controls, which could not provide sufficient statistical power to detect all possible effects of TGF-b1 gene polymorphisms (TGF-b1 T869C and TGF-b1 T29C) on PMOP. Second, small sample size of the study by Tural et al 17 and 3 studies 13, 15, 16 that was not consistent with HWE might contribute to the contrasting results and influence the conclusions drawn. Third, only 2 studies 17, 21 were performed in Caucasian population, which may indicate a race-specific effect. Therefore, larger-scale and better-designed studies are necessary to determine the association between TGF-b1 gene polymorphisms (TGF-b1 T869C and TGF-b1 T29C) and the risk of PMOP.
CONCLUSION
In conclusion, in this meta-analysis we pooled all the available data related to TGF-b1 T869C and TGF-b1 T29C polymorphisms and PMOP risk, and found that the TGF-b1 T869C and TGF-b1 T29C polymorphisms may be involved in the susceptibility to PMOP, especially in Asian patients. Therefore, more studies are required to overcome the aforementioned limitations to further assess the association of TGF-b1 T869C and TGF-b1 T29C polymorphisms with increased susceptibility to PMOP.
